drugset / Trial / NCT05514899

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

NCT05514899 ↗

Phase 2 Recruiting 90 enrolled University of California, San Diego
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures designed to monitor subject safety and measure the effects of the study drug.

Timeline

Start
2023-09-01
Primary completion
2027-10-31
Completion
2027-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CBD Unknown 600 mg Oral
Subject THC Unknown 10 mg Oral